Adeno-associated Virus-Delivered Alpha Synuclein Inhibits Bladder Cancer Growth Via the P53/p21 Signaling Pathway.

Zhengcun Wu,Chengxing Xia,Chao Zhang,Donghong Tang,Feineng Liu,Yitian Ou,Jiahong Gao,Hongkun Yi,Delin Yang,Kaili Ma
DOI: https://doi.org/10.1038/s41417-022-00425-w
IF: 5.854
2022-01-01
Cancer Gene Therapy
Abstract:Alpha-synuclein (α-syn), encoded by the SNCA gene, is a major participant in the pathophysiology of Parkinson's disease (PD). Its functions have been reported to be related to apoptosis induction, the elevation of oxidative stress, mitochondrial homeostasis, cell-cycle aberrations, and DNA-related interactions. Evidence obtained in recent studies suggests a possible link between α-syn and cancer development. Bladder cancer (BCa) is the second most common genitourinary malignancy, with the population of survivors of BCa increasing worldwide. In this study, we show that α-syn expression was significantly downregulated in BCa. In vitro and in vivo experiments showed that α-syn could significantly inhibit BCa cell proliferation by arresting the cell cycle in the S phase via upregulation of p53 expression mediated by DNA damages. Further experiments showed that overexpression of α-syn delivered by adeno-associated viruses (AAVs) exerted inhibitory effects on the growth of BCa tumors. These findings indicate that αα-syn is a functional tumor suppressor that can inhibit the proliferation of BCa cells by activating the p53/p21 signaling pathway. Our present study provides insights into the roles of α-syn in BCa and suggests that α-syn may be a novel therapeutic target for the treatment of BCa.
What problem does this paper attempt to address?